Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Nott

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Nuclear Medicine Communications|December 1, 1987
Induced hepatic arterial blockade by degradable starch microspheres in the ratD M Nott, J Yates, J S Grime, et al.
Journal of Magnetic Resonance Imaging : JMRI|January 25, 2005
Interstudy reproducibility of three-dimensional volume-selective fast spin echo magnetic resonance for quantifying carotid artery wall volumeAnitha Varghese, Lindsey A Crowe, Raad H Mohiaddin, et al.
European Journal of Cancer (Oxford, England : 1990)|December 31, 2019
Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinomaFrede Donskov, Robert J Motzer, Eric Voog, et al.
Clinical Colorectal Cancer|November 23, 2018
Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM StudyJeremy D Shapiro, Subotheni Thavaneswaran, Craig R Underhill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2013
Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 TrialLillian L Siu, Jeremy D Shapiro, Derek J Jonker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2016
Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM StudyEva Segelov, Subotheni Thavaneswaran, Paul M Waring, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trialA P Barbour, E T Walpole, G T Mai, et al.
Medical Teacher|August 24, 2021
The impact of the COVID-19 pandemic on UK medical education. A nationwide student surveyNicholas Pari Tekkis, Damir Rafi, Sam Brown, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Nuclear Medicine Communications|December 1, 1987
Induced hepatic arterial blockade by degradable starch microspheres in the ratD M Nott, J Yates, J S Grime, et al.
Journal of Magnetic Resonance Imaging : JMRI|January 25, 2005
Interstudy reproducibility of three-dimensional volume-selective fast spin echo magnetic resonance for quantifying carotid artery wall volumeAnitha Varghese, Lindsey A Crowe, Raad H Mohiaddin, et al.
European Journal of Cancer (Oxford, England : 1990)|December 31, 2019
Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinomaFrede Donskov, Robert J Motzer, Eric Voog, et al.
Clinical Colorectal Cancer|November 23, 2018
Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM StudyJeremy D Shapiro, Subotheni Thavaneswaran, Craig R Underhill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2013
Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 TrialLillian L Siu, Jeremy D Shapiro, Derek J Jonker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2016
Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM StudyEva Segelov, Subotheni Thavaneswaran, Paul M Waring, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trialA P Barbour, E T Walpole, G T Mai, et al.
Medical Teacher|August 24, 2021
The impact of the COVID-19 pandemic on UK medical education. A nationwide student surveyNicholas Pari Tekkis, Damir Rafi, Sam Brown, et al.
Pageof 7